Merck & Co Inc’s (NYSE:MRK) rVSV-ZEBOV vaccine is the only WHO-prequalified vaccine endorsed by the Strategic Advisory Group of Experts on Immunization for use in Ebola outbreaks caused by the Zaire ebolavirus.
The FDA approved the vaccine for adults in December 2019 and for use in children 12 months and older in August 2023.
Researchers conducted a retrospective test-negative analysis to estimate the effectiveness of rVSV-ZEBOV vaccination against Ebola virus disease during the 2018–20 epidemic in the Democratic Republic of the Congo.
The data showed that 1,273 (4·8%) of 26,438 eligible individuals were positive for Ebola virus disease (cases), and 25,165 (95·2%) were negative (controls).
Also Read: ...
